SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending following a strong earnings report and positive guidance, with community members actively discussing the potential for a short squeeze and future partnerships with hyperscalers. Talk centers around the company's role in AI infrastructure and potential for significant growth. Some investors are warning of overbought conditions and the risks of algorithmic selling, while others remain extremely bullish, citing the company's long-term potential.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ (LAES) is trending due to its partnership to develop quantum-resistant chips for U.S. defense, fueling speculation about government contracts. The community is discussing its potential for significant growth and comparing it favorably to other quantum stocks. Many believe LAES is undervalued and poised for a substantial run, possibly reaching double digits soon.

One and one Green Technologies. Inc - Ordinary Shares - Class A

YDDL is trending due to its recent IPO and subsequent after-hours surge, fueled by its low float and significant insider ownership. Community members are discussing potential for continued momentum and comparing it to other AI and low-float stocks, while also noting its association with waste management in the Philippines. Traders are watching for potential scalping opportunities, halt patterns, and VWAP reclaims.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending as community members discuss its breakout potential and momentum in the automation space, drawing comparisons to Palantir. Some traders are pointing to strong call volume and AI tailwinds as potential catalysts, while others highlight the company's partnerships and potential for a short squeeze. The stock's potential in the AI infrastructure wave is also fueling bullish sentiment.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf ($WULF) is trending as investors discuss its potential for a short squeeze, fueled by high short interest and recent institutional investment. Community members are also excited about the company's vision and potential connection to clean-energy nuclear reactors for AI infrastructure. The stock is gaining attention as discussions around TeraWulf's pivot towards AI and high-performance computing data centers intensifies, with some comparing it to sector peers.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as community members debate whether its valuation is justified amidst a significant rally, with some pointing to the potential for a short squeeze and others warning of an impending correction. Bullish sentiment focuses on the future of quantum computing, while bears highlight the company's current financials and question its high market capitalization. Some traders are closely watching for a potential offering, believing it could impact the stock's trajectory.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as chatter increases about its merger with Infleqtion, a quantum computing company, with comparisons being drawn to sector peers like $NVDA. Community members highlight Infleqtion's existing government contracts and potential for growth, viewing the stock as undervalued relative to competitors and pointing to a potential 10X run. Discussions also include the warrants ($CCCXW) as a means for maximizing potential gains.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as the community discusses its potential for significant growth, with some drawing comparisons to IREN and anticipating a run to higher price levels. Chatter revolves around a possible short squeeze, upcoming news related to AI/HPC, and the company's strong position in the Bitcoin mining sector amid rising cryptocurrency prices. Some are also following news of executive networking and potential government partnerships.

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

ORBS is trending as traders discuss recent price volatility and potential catalysts. Community members are debating whether the stock's pullback presents a buying opportunity, while also speculating about news related to Worldcoin and upcoming events involving Dan Ives. Some traders suggest a potential squeeze given the small float, while others express concern about potential dilution.

GSR III Acquisition Corp engages in the merger, share exchange, asset acquisition, share purchase or reorganization with one or more businesses. The company was founded on May 10, 2023 and is headquartered in Austin, Texas.

GSR III Acquisition Corp. - Ordinary Shares- Class A

GSR III Acquisition Corp. Ordinary Shares

GSRT (soon to be NKLR) is trending as the ticker change approaches, sparking excitement among investors eager to capitalize on the burgeoning nuclear micro-reactor sector. Community members are drawing comparisons to OKLO and anticipating a potential surge, fueled by the increasing demand for scalable, clean energy solutions and the nuclear sector's increasing relevance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 40.4% in Schrodinger (SDGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Schrodinger shares came under pressure after Citi pulled back its bullish call, cutting the stock to ‘Neutral’ from ‘Buy’ and slashing its price target to $20 from $35.&nbsp;The firm said recent stumbles in Schrodinger’s homegrown drug programs, along with persistent headwinds across biotech and pharma, have dimmed its outlook.<a href="https://stocktwits.com/symbol/SDGR">Shares of Schrodinger</a> fell 2% to $19.45 on Thursday, marking its lowest close in four months, before edging up 0.2% to $19.5 in after-hours trading.The downgrade by the brokerage firm came just after Schrodinger disclosed that it will&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/schrodinger-discontinues-clinical-program-after-two-patient-deaths/chsR0RyRdOb">discontinue the development of SGR-2921</a>, an early-stage CDC7 inhibitor, for the treatment of patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.Chief Medical Officer Margaret Dugan said patient safety was the company’s top priority, noting that the drug’s potential as a combination therapy would be challenging to pursue under the circumstances. “While disappointing given the early clinical activity observed, we believe this is the right decision for patients,” she said.Citi said its earlier bullish stance had hinged on three early-stage Phase 1 assets that could validate Schrodinger’s drug discovery platform and attract biopharma partners.&nbsp;The brokerage firm noted that updates so far have “fallen short,” fueling concerns about the future of the company’s internal drug portfolio.SGR-2921 was&nbsp;designed to block CDC7 kinase, a protein overexpressed in many cancers and involved in DNA replication and cell cycle progression.&nbsp;Preclinical data had suggested the drug could work in combination with standard-of-care agents, but Schrodinger said the safety risks outweighed the potential benefits.On Stocktwits, retail sentiment for Schrodinger was ‘bearish’ amid ‘extremely high’ message volume.One user questioned the timing of Schrodinger’s disclosure, noting that the company reported Q2 earnings just eight days ago, and&nbsp;wondered if both patient deaths occurred since then or if the information had been withheld.&nbsp;<stembedurl>https://stocktwits.com/scott52/message/625133866</stembedurl>Another user speculated that there was “more to the news” than disclosed, pointing to the stock’s quick price recovery as a sign that “something fishy” might be going on.<stembedurl>https://stocktwits.com/Buckanator/message/625153259</stembedurl>Schrodinger’s stock has risen 0.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Schrodinger logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Schrodinger Downgraded By Citi After Ending Blood Cancer Drug Trial Tied To 2 Deaths; Retail Voices Concern

Shares closed at a four-month low before edging slightly higher after hours as investors digested the pipeline setback and cautious outlook.

Equity

Schrödinger, Inc. (SDGR) announced on Thursday that it is discontinuing the clinical development program for SGR-2921, which was being evaluated in an early-stage study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.The decision was made in light of two treatment-related deaths in the early-stage study, the company said. <a href="https://stocktwits.com/symbol/SDGR">Schrödinger</a> opined that developing the drug as a combination therapy would be difficult to pursue in light of the two deaths despite evidence of activity as a monotherapy.Margaret Dugan, chief medical officer at Schrödinger, <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.schrodinger.com/press-releases/news-details/2025/Schrdinger-Announces-Discontinuation-of-SGR-2921-Program/default.aspx">said</a>, “Patient safety is our first priority, and in light of two treatment-related deaths in the Phase 1 dose-escalation study, we have made the decision to discontinue further development of SGR-2921. While disappointing given the early clinical activity observed, we believe this is the right decision for patients.”On Stocktwits, retail sentiment around SDGR fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels. The stock is trading 4% lower in the pre-market session on Thursday.Dugan said the company had hoped to advance the investigational drug for acute myeloid leukemia, a rapidly progressing cancer of the blood and bone marrow, provided there are limited therapies available for the disease. The early-stage study was also supported by preclinical data, which suggested that SGR-2921 could ultimately be used in combination with standard-of-care agents, the company said.SGR-2921 is a CDC7 inhibitor, meaning it is a drug that blocks the activity of the CDC7 kinase, a protein involved in DNA replication and cell cycle progression. CDC7 is often overexpressed in cancer cells, and its inhibition can lead to cell cycle arrest and programmed cell death of these cancer cells.SDGR stock is up by 3% this year and by over 4% in the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-lower-as-investors-await-wholesale-inflation-data/chsRirXRdOG">Dow Futures Edge Lower As Wall Street Watches Out For PPI Report: BLSH, COHR, CSCO Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Schrödinger Discontinues Clinical Program After Two Patient Deaths

SGR-2921 was being evaluated in an early-stage study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates

Schrodinger (SDGR) delivered earnings and revenue surprises of +28.92% and +5.08%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Clover Health Investments, Corp. (CLOV) Q2 Earnings Meet Estimates

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 0.00% and -1.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition?

VEEV leans on Vault R&D for growth as AI-native rivals rise, testing its edge in clinical and regulatory innovation.

Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?

Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.

Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Schrodinger (SDGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Schrodinger Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

SDGR
Schrodinger Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SDGR News

SDGRSchrodinger Inc